Determination of naloxone-3-glucuronide in human plasma and urine by HILIC-MS/MS

Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences

Volumn 942-943, Issue , 2013, Pages 83-87

  Dong, Ji ^a,c   Liu, Shuaibing ^a   Zhang, Hua ^a   Hua, Qianli ^b   Zhao, Xuegang ^b   Miao, Liyan ^a,c  

^a THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b Aoxing Pharmaceutical Company   (China)

^c SOOCHOW UNIVERSITY   (China)

Author keywords

HILIC MS MS; Naloxone 3 glucuronide; Pharmacokinetics

Indexed keywords

CHROMATOGRAPHIC SEPARATIONS; DIRECT DETERMINATION; HILIC-MS/MS; HYDROPHILIC INTERACTION; MULTIPLE-REACTION MONITORING MODES; NALOXONE-3-GLUCURONIDE; PROTEIN PRECIPITATION; RELATIVE STANDARD DEVIATIONS;

ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; PHARMACOKINETICS; PLASMA (HUMAN);

BODY FLUIDS;

GLUCURONIC ACID; NALOXONE; NALOXONE 3 GLUCURONIDE; NALTREXONE DERIVATIVE; TILIDINE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EXCRETION; DRUG HYDROLYSIS; DRUG URINE LEVEL; ELECTROSPRAY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; HYDROLYSIS; HYDROPHILIC INTERACTION CHROMATOGRAPHY; MAXIMUM PLASMA CONCENTRATION; MEASUREMENT ACCURACY; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; QUADRUPOLE MASS SPECTROMETRY; TANDEM MASS SPECTROMETRY; URINALYSIS; URINARY EXCRETION;

HILIC-MS/MS; NALOXONE-3-GLUCURONIDE; PHARMACOKINETICS;

ADMINISTRATION, ORAL; ADULT; CHROMATOGRAPHY, LIQUID; HUMANS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; LIMIT OF DETECTION; NALOXONE; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 84887340346     PISSN: 15700232     EISSN: 1873376X     Source Type: Journal    
DOI: 10.1016/j.jchromb.2013.09.036     Document Type: Article

References (17)

1. Choi Y.S., Billings J.A. J. Pain Symptom Manage. 2002, 24:71.
2. Brennscheidt U., Seiler K.U., Thomann P. Arzneim. Forsch. 2000, 50:1015.
3. Hengy H., Vollmer K.O., Gladigau V. J. Pharm. Sci. 1978, 67:1765.
4. Liu M., Wittbrodt E. J. Pain Symptom Manage. 2002, 23:48.
5. Smith K., Hopp M., Mundin G., Leyendecker P., Bailey P., Grothe B., Uhl R., Reimer K. Clin. Ther. 2008, 30:2051.
6. Kaushik R., Levine B., LaCourse W.R. Anal. Chim. Acta 2006, 556:225.
7. Al-Asmari A.I., Anderson R.A. J. Anal. Toxicol. 2007, 31:394.
8. Olsen B.A. J. Cromatogr. A 2001, 913:113.
9. Layne J. J. Chromatogr. A 2002, 957:149.
10. Hanai T. J. Chromatogr. A 2003, 989:183.
11. Reid T.S., Henry R.A. Am. Lab. 1999, 7:24.
12. Naidong W., Shou W., Chen Y.L., Jiang X. J. Chromatogr. B: Biomed. Sci. Appl. 2001, 754:387.
13. Alpert A.J. J. Chromatogr. 1990, 499:177.
14. EMEA, 2011, . http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500109686.pdf.
15. Gibaldi M., Perrier D. Pharmacokinetics 1982, vol. 15:407. M. Dekker, New York, NY. 2nd ed.
16. Brennscheidt U., Brunnmuller U., Proppe D., Thomann P., Seiler K.U. Arzneim. Forsch. 2007, 57:106.
17. Fang W.B., Chang Y., McCance-Katz E.F., Moody D.E. J. Anal. Toxicol. 2009, 33:409.